CD274 and breast carcinoma: Among 22 NSCLC patients, IHC of PD-L1 using the 22C3 antibody was possible in 19 patients except for 1 patient each where EBUS-TBNA was performed to differentiate between lung and breast cancer recurrence for staging purposes and to search for T790M mutation in EGFR-positive NSCLC, respectively.